Coagulation factors are protein components of the blood which serve blood coagulation.
Search results 51 to 75 from a total of 90
| Name | Marketing Authorisation Holder | License Number | License Date | Further Information |
|---|---|---|---|---|
|
IMMUNATE 500 I.E. |
Takeda GmbH |
3854.02.00 | 20.10.1983 | |
|
IMMUNATE 1000 I.E. |
Takeda GmbH |
3854.03.00 | 20.10.1983 | |
IMMUNINE 600 I.E. |
Takeda GmbH |
PEI.H.03595.02.1 | 05.05.2008 | |
IMMUNINE 1200 I.E. |
Orifarm GmbH |
PEI.H.12094.01.1 | 24.03.2021 | |
IMMUNINE 1200 I.E. |
Takeda GmbH |
PEI.H.03595.03.1 | 05.05.2008 | |
|
Immuseven |
Takeda GmbH |
PEI.H.03341.01.1 | 28.11.2005 | |
Jivi |
Bayer AG |
EU/1/18/1324 | 22.11.2018 | |
|
Kovaltry |
Bayer AG |
EU/1/15/1076 | 18.02.2016 | |
|
NovoEight |
Novo Nordisk A/S, Denmark |
EU/1/13/888 | 13.11.2013 | |
|
NovoSeven |
Novo Nordisk A/S |
EU/1/96/006 | 23.02.1996 | |
|
NovoThirteen |
Novo Nordisk A/S, Denmark |
EU/1/12/775 | 03.09.2012 | |
|
Nuwiq |
Octapharma AB, Stockholm |
EU/1/14/936 | 22.07.2014 | |
|
Obizur |
Baxalta Innovations GmbH, A |
EU/1/15/1035 | 11.11.2015 | |
|
Octanate 250 |
OCTAPHARMA GmbH |
10500a/97-1 | 04.08.1998 | |
|
Octanate 500 |
OCTAPHARMA GmbH |
10500a/97-2 | 04.08.1998 | |
Octanate 1000 |
CC-Pharma GmbH |
PEI.H.12112.01.1 | 05.07.2021 | |
|
Octanate 1000 |
OCTAPHARMA GmbH |
10500a/97-3 | 04.08.1998 | |
Octanate 1000 |
Orifarm GmbH |
PEI.H.12088.01.1 | 24.03.2021 | |
|
OCTANINE F 500 |
OCTAPHARMA GmbH |
10501a/97-2 | 07.09.2000 | |
|
OCTANINE F 1000 |
OCTAPHARMA GmbH |
10501a/97-3 | 07.09.2000 | |
|
OCTAPLEX 500 |
OCTAPHARMA GmbH |
PEI.H.02312.01.1 | 14.03.2003 | |
|
Octaplex 1000 |
OCTAPHARMA GmbH |
PEI.H.02312.02.1 | 11.08.2015 | |
Prothromplex NF 500 |
Takeda GmbH |
PEI.H.11717.02.1 | 21.04.2023 | |
Prothromplex NF 600 |
Takeda GmbH |
PEI.H.11717.01.1 | 13.08.2014 | |
Recombinate Antihaemophilie Faktor (rekombinant) 1000 |
Takeda GmbH |
28530.02.00 | 30.07.1993 |
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 520 in BAnz AT 22.08.2024 B6.
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.
Updated: 22.08.2024
